Insulin pump therapy started at the time of diagnosis: Effects on glycemic control and pancreatic β-cell function in type 1 diabetes

Diabetes Technology and Therapeutics

Volumn 13, Issue 10, 2011, Pages 1023-1030

  Thrailkill, Kathryn M ^a,b   Moreau, Cynthia S ^a,b   Swearingen, Christopher ^a,b   Rettiganti, Mallik ^a,b   Edwards, Kathy ^a,b   Morales, Alba E ^a,b   Kemp, Stephen F ^a,b   Frindik, J Paul ^a,b   Fowlkes, John L ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG UTILIZATION; FEMALE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN RELEASE; MALE; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SCHOOL CHILD;

ADOLESCENT; BLOOD GLUCOSE; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN-SECRETING CELLS; MALE; PATIENT SATISFACTION; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 80053415705     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0085     Document Type: Article

References (26)

1. Eisenbarth GS: Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986;314:1360-1368. (Pubitemid 16122469)
2. van Belle TL, Coppieters KT, von Herrath MG: Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol Rev 2011;91:79-118.
3. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC: Insulin secretion in type 1 diabetes. Diabetes 2004;53:426-433. (Pubitemid 38174559)
4. Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, Bonner-Weir S, King GL: Residual insulin production and pancreatic b-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853.
5. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998;128:517-523.
6. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R: Insulin pump therapy: A meta-analysis. Diabetes Care 2003;26:1079-1087. (Pubitemid 36929252)
7. Willi SM, Planton J, Egede L, Schwarz S: Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003;143:796-801. (Pubitemid 37510652)
8. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group: Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-320.
9. Shah SC, Malone JI, Simpson NE: A randomized trial of intensive insulin therapy in newly diagnosed insulindependent diabetes mellitus. N Engl J Med 1989;320:550-554. (Pubitemid 19070538)
10. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, Deeb L, Grey M, Anderson B, Holzmeister LA, Clark N; American Diabetes Association: Care of children and adolescents with type 1 diabetes: A statement of the American Diabetes Association. Diabetes Care 2005;28:186-212. (Pubitemid 40095803)
11. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: Report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264. (Pubitemid 38044724)
12. Shiang K: The SAS calculations of areas under the curve (AUC) for multiple metabolic readings. In: SAS Conference Proceedings: Western Users of SAS Software 2004. www.lexjansen.com/wuss/2004/posters/c-post-the-sas- calculations-pdf (accessed June 13, 2011).
13. Rodbard D: New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009;11:551-565.
14. Lin L: A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-268. (Pubitemid 19109172)
15. Mortensen HB, Hougaard P, Swift P, Hansen L, Holl RW, Hoey H, Bjoerndalen H, de Beaufort C, Chiarelli F, Danne T, Schoenle EJ, Aman J; Hvidoere Study Group on Childhood Diabetes: New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009;32:1384-1390.
16. Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F: Use of insulin pump therapy in the pediatric age-group: Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007;30:1653-1662. (Pubitemid 46871195)
17. Jeha GS, Karaviti LP, Anderson B, Smith EO, Donaldson S, McGirk TS, Haymond MW: Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decreases glucose excursions and the risk of hypoglycemia. Diabetes Technol Ther 2005;7:876-884. (Pubitemid 43133994)
18. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV: Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779-1784. (Pubitemid 29521861)
19. Muller-Godeffroy E, Treichel S, Wagner VM: Investigation of quality of life and family burden issues during insulin pump therapy in children with Type 1 diabetes mellitus-a large-scale multicentre pilot study. Diabet Med 2009;26:493-501.
20. Pankowska E, Nazim J, Szalecki M, Urban M: Equal metabolic control but superior caregiver treatment satisfaction with insulin aspart in preschool children. Diabetes Technol Ther 2010;12:413-418.
21. Ramchandani N, Ten S, Anhalt H, Sinha S, Ching J, Finkelstein A, Maclaren NK: Insulin pump therapy from the time of diagnosis of type 1 diabetes. Diabetes Technol Ther 2006;8:663-670. (Pubitemid 44871496)
22. Kordonouri O, Pankowska E, Rami B, Kapellen T, Coutant R, Hartmann R, Lange K, Knip M, Danne T: Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: Results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 2010;53:2487-2495.
23. Pozzilli P, Crinó A, Schiaffini R, Manfrini S, Fioriti E, Coppolino G, Pitocco D, Visalli N, Corbi S, Spera S, Suraci C, Cervoni M, Matteoli MC, Patera IP, Ghirlanda G; IMDIAB Group: A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). Diabetes Technol Ther 2003;5:965-974. (Pubitemid 38009934)
24. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R: GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-1920.
25. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group: Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009;132:166-173.
26. Morales AE, Thrailkill KM: GAD-alum immunotherapy in Type 1 diabetes mellitus. Immunotherapy 2011;3:323-332.